Burlingame, CA, Nov. 13, 2025 (GLOBE NEWSWIRE) — The Global Usher Syndrome Market is estimated to be valued at USD 2.29 Bn in 2025 and is expected to reach USD 3.20 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.9% from 2025 to 2032. This consistent growth is driven by rising awareness and improved diagnosis of Usher syndrome, supported by advancements in genetic testing and emerging treatment options that are expected to fuel market expansion throughout the forecast period.
Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/8526
Global Usher Syndrome Market Key Takeaways
According to Coherent Market Insights (CMI), the global usher syndrome market size is projected to grow at a CAGR of 4.9% during the forecast period, reaching USD 3.20 Bn by 2032, up from USD 2.29 Bn in 2025.
Usher syndrome type II category is slated to dominate the industry, capturing 54.5% of the market share in 2025.
Based on diagnosis, genetic testing segment is expected to account for nearly one-fourth of the global usher syndrome market share by 2025.
Gene therapy remains a highly sought-after treatment for usher syndrome, with the target segment poised to account for 32.3% of the market share in 2025.
North America is set to maintain its dominance, accounting for 38.2% of the global usher syndrome industry share in 2025.
Asia Pacific, with an estimated share of 24.2% in 2025, is slated to emerge as the most lucrative market for usher syndrome treatments and diagnostic tools.
Improved Diagnostic Technologies Fueling Market Growth
Coherent Market Insights’ new usher syndrome market analysis outlines major factors spurring industry growth. Advancements in diagnostic technologies and increasing number of diagnosed usher syndrome cases are among the most prominent growth drivers.
Advanced diagnostic tools like next-generation sequencing (NGS), electroretinography (ERG), and optical coherence tomography (OCT) are making Usher syndrome diagnosis faster, more accurate, and increasingly accessible. These improvements are expected to drive growth of usher syndrome market during the forecast period.
More diagnosed usher syndrome cases due to improved diagnostics means a large patient pool. As a result, demand for usher syndrome treatments like gene therapy, cochlear implants, hearing aids, and retinal implants is set to increase steadily in the coming years.
Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/8526
High Cost of Advanced Therapies Limiting Usher Syndrome Market Growth
The global usher syndrome market outlook remains positive, owing to growing awareness and early diagnosis. However, high cost of advanced therapies might limit market growth to some extent during the forthcoming period.
Gene and cell-based therapies are often expensive to develop and manufacture. High cost of these advanced therapies can limit patient access, especially in low-resource settings, thereby dampening overall usher syndrome market demand.
Similarly, cutting-edge hearing and retinal implants can be costly. This may deter some patients from adopting these solutions, potentially slowing down growth of the usher syndrome market.
Genetic Research and Therapy Advancements Creating Growth Opportunities
New genetic therapies are being researched for inherited retinal diseases like Usher syndrome. For example, the gene therapy LUCE-1 is being developed for Usher Syndrome Type 1B (USH1B). This therapy aims to protect retinal cells and slow down vision loss. Such developments in gene therapy are expected to create new opportunities in the Usher syndrome market during the coming years.
Emerging Usher Syndrome Market Trends
Introduction of innovative assistive devices is a key trend in the usher syndrome market. Advanced hearing aids, cochlear implants, and vision aids are being developed to improve the quality of life of individuals with usher syndrome. These technological advancements are driving market growth by enhancing sensory support for patients.
Governments and research institutions worldwide are increasing funding for rare disease research, including Usher syndrome. Initiatives such as screening programs and clinical trials are expected to create a supportive environment for the expansion of the Usher syndrome market during the forecast period.
Partnerships and collaborations are becoming popular in the usher syndrome industry. Biotech companies, academic labs, and research institutions are collaborating to advance rare disease therapies. For instance, in December 2024, Usher Syndrome Coalition partnered with Sepul Bio to support the LUNA clinical trial. Similarly, the University of Houston received a $1.1 million grant from the Cynthia and George Mitchell Foundation to advance research on Usher syndrome, focusing on innovative gene therapy approaches.
Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/8526
Analyst’s View
“The global usher syndrome industry is set to grow steadily owing to rising number of diagnosed cases, advancements in diagnostic technologies and gene therapies, introduction of advanced hearing and vision aids, and supportive government initiatives,” said a senior analyst at CMI.
Current Events and Their Impact on the Usher Syndrome Market
| Event | Description and Impact |
| Gene and Cell Therapy Breakthroughs |
|
| Technological Innovation and Digital Health Integration |
|
| Strategic Industry Consolidation and Partnerships |
|
Competitor Insights
Key companies in the usher syndrome market report:
- AAVantgarde Bio
- Laboratoires Théa (Sepul Bio)
- Atsena Therapeutics
- Nanoscope Therapeutics
- Nacuity Pharmaceuticals
- GenSight Biologics
- Odylia Therapeutics
- Cochlear Limited
- MED-EL Medical Electronics
- Demant (Oticon)
- Starkey Hearing Technologies
- GN Hearing (ReSound)
- WS Audiology (Signia, Widex)
- Advanced Bionics (a Sonova brand)
Key Developments
In July 2025, Cochlear Limited received U.S. FDA approval for the Cochlear Nucleus Nexa System, the world’s first and only smart cochlear implant system. This new device will likely help patients with conditions like sensorineural hearing loss, including those affected by conditions such as Usher syndrome.
In October 2024, ReiThera supplied drug substance and finished drug product for AAVantgarde’s groundbreaking gene therapy trial for Usher Syndrome Type 1B. AAVantgarde Bio started the trial LUCE-1 to test their AAVB-081 gene therapy for retinitis pigmentosa caused by usher syndrome Type 1B.
Market Segmentation
Type Insights (Revenue, USD Bn, 2020 – 2032)
- Usher syndrome Type II
- Usher syndrome Type I
- Usher syndrome Type III
Diagnosis Insights (Revenue, USD Bn, 2020 – 2032)
- Genetic Testing
- Electroretinogram (ERG)
- Optical Coherence Tomography (OCT)
- Videonystagmography
- Audiological Testing
- Others (e.g., Clinical Evaluation, Imaging Tools)
Treatment Insights (Revenue, USD Bn, 2020 – 2032)
- Gene Therapy
- Cochlear Implants and Hearing Aids
- Retinal Implants and Vision Aids
- Rehabilitation and Assistive Devices
- Supportive Therapies (Speech, Physical, Occupational)
Patient Age Group Insights (Revenue, USD Bn, 2020 – 2032)
- Pediatric
- Adult
Distribution Channel Insights (Revenue, USD Bn, 2020 – 2032)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
End User Insights (Revenue, USD Bn, 2020 – 2032)
- Hospitals and Clinics
- Specialty Centers (ENT, Ophthalmology, Genetic)
- Homecare Settings
- Others (Research and Academic Institutes)
Regional Insights (Revenue, USD Bn, 2020 – 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Related Reports:
Genetic Testing Market Analysis & Forecast for 2025-2032
Gene Therapy Market Size, Share, Trends & Opportunities for 2025-2032
Cochlear Implants Market Outlook for 2025-2032
Our Trusted Partners:
Worldwide Market Reports, Coherent MI, Stratagem Market Insights
Get Recent News:
https://www.coherentmarketinsights.com/news
CONTACT: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Contact Us: Mr. Shah Coherent Market Insights 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States US: + 12524771362 UK: +442039578553 AUS: +61-8-7924-7805 India: +91-848-285-0837 Email: [email protected] Website: https://www.coherentmarketinsights.com For Latest Update Follow Us: LinkedIn | Facebook | Twitter
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.